Last $0.08 USD
Change Today +0.002 / 2.60%
Volume 2.2M
AMBS On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

amarantus bioscience holding (AMBS) Snapshot

Open
$0.08
Previous Close
$0.08
Day High
$0.08
Day Low
$0.08
52 Week High
07/29/14 - $0.20
52 Week Low
12/1/14 - $0.05
Market Cap
63.2M
Average Volume 10 Days
2.2M
EPS TTM
$-0.05
Shares Outstanding
799.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AMARANTUS BIOSCIENCE HOLDING (AMBS)

Related News

No related news articles were found.

amarantus bioscience holding (AMBS) Related Businessweek News

No Related Businessweek News Found

amarantus bioscience holding (AMBS) Details

Amarantus BioScience Holdings, Inc., a biotechnology company, engages in discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis. Its lead therapeutic program Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) is a targeted therapeutic to address the underlying programmed cell death (apoptosis) associated with a range of devastating human disorders with a priority to identify drug able orphan indications, including Retinitis Pigmentosa. The company’s principal products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer’s disease; and Eltoprazine, a small molecule drug candidate, which is used for the treatment of Parkinson’s disease medication Levadopa-Induced Dyskinesia and Adult Attention Deficit Hyperactivity Disorders that is in Phase II clinical trials. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson’s disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus Bioscience Holdings, Inc. in April 2013. Amarantus Bioscience Holdings, Inc. was founded in 2008 and is based in San Francisco, California.

3 Employees
Last Reported Date: 06/20/14
Founded in 2008

amarantus bioscience holding (AMBS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $230.1K
Vice President of Financial Operations, Corpo...
Total Annual Compensation: $261.0K
Chief Scientific Officer, Director and Member...
Total Annual Compensation: $213.8K
Compensation as of Fiscal Year 2013.

amarantus bioscience holding (AMBS) Key Developments

Amarantus BioScience Holdings, Inc. Submits Orphan Drug Designation Application to US FDA for Treatment of Retinal Artery Occlusion with Product Candidate MANF

Amarantus BioScience Holdings Inc. announced that it has applied to the U.S. Food & Drug Administration for Orphan Drug Designation for its investigational drug MANF (mesencephalic-astrocyte-derived neurotrophic factor) as a treatment for retinal artery occlusion. RAO is a blockage of the blood supply to the retina which causes severe and sudden loss of vision. MANF, a naturally-occurring protein that reduces and prevents apoptosis (programmed cell death) in response to injury or disease, was discovered utilizing Amarantus' proprietary PhenoGuardTM Protein Discovery Engine. Pre-clinical data showed that MANF provided protective functional effects in an animal model of RAO. Moreover, toxicology studies have demonstrated that MANF was well-tolerated following a single intravitreal administration of a therapeutically relevant dose. The FDA Orphan Drug Designation program provides a special status to drugs and biologics intended to treat, diagnose or prevent so-called orphan diseases and disorders that affect fewer than 200,000 people in the U.S. This designation provides for a seven-year marketing exclusivity period against competition, as well as certain incentives, including federal grants, tax credits and a waiver of PDUFA filing fees.

Amarantus Bioscience Holdings, Inc. Appoints Elise Brownell as Senior Vice President of Operations and Project Management

Amarantus Bioscience Holdings Inc. announced the appointment of Elise Brownell to the newly created position of Senior Vice President of Operations and Program Management. Dr. Brownell brings more than 20 years of biotechnology and pharmaceutical project management experience with a track record of advancing programs through clinical development. She serves as a Life Sciences entrepreneurial advisor for ASTIA. Dr. Brownell is also a member of the Editorial Advisory Board for Contract Pharma Magazine, and previous Chair of the Leaders Network program of Women in Consulting.

Amarantus Appoints Joseph Rubinfeld to its Board of Directors

Amarantus BioScience Holdings Inc. announced the appointment of Joseph Rubinfeld, Ph.D. to its Board of Directors. Dr. Rubinfeld is a renowned expert in the field of drug development, and a co-founder of Amgen, one of the most successful companies in the history of the biotechnology industry. Dr. Rubinfeld brings more than 40 years of biopharmaceutical leadership experience to Amarantus' Board of Directors. Dr. Rubinfeld is currently a Board member of Regenicin Inc. and CytRx Corporation.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMBS:US $0.08 USD +0.002

AMBS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AMBS.
View Industry Companies
 

Industry Analysis

AMBS

Industry Average

Valuation AMBS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMARANTUS BIOSCIENCE HOLDING, please visit www.amarantus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.